DrugPatentWatch Database Preview
Drugs in Development Information for Galeterone
» See Plans and Pricing
What is the development status for investigational drug Galeterone?
Galeterone is an investigational drug.
There have been 4 clinical trials for Galeterone.
The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2015.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Pancreatic Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Tokai Pharmaceuticals, University of Maryland, Baltimore, and [disabled in preview].
There are twenty-three US patents protecting this investigational drug and one hundred and fourteen international patents.
Summary for Galeterone
| US Patents | 23 |
| International Patents | 114 |
| US Patent Applications | 60 |
| WIPO Patent Applications | 259 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2015-06-01) |
| Vendors | 46 |
Recent Clinical Trials for Galeterone
| Title | Sponsor | Phase |
|---|---|---|
| 1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma | University of Maryland, Baltimore | Phase 2 |
| Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Galeterone | Tokai Pharmaceuticals | Phase 1 |
| A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC | Tokai Pharmaceuticals | Phase 3 |
Clinical Trial Summary for Galeterone
Top disease conditions for Galeterone
Top clinical trial sponsors for Galeterone
US Patents for Galeterone
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Galeterone | Start Trial | Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof | The Trustees of the University of Pennsylvania (Philadelphia, PA) | Start Trial |
| Galeterone | Start Trial | C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity | UNIVERSITY OF MARYLAND BALTIMORE (Baltimore, MD) | Start Trial |
| Galeterone | Start Trial | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | Vanderbilt University (Nashville, TN) The Trustees of the University of Pennsylvania (Philadelphia, PA) | Start Trial |
| Galeterone | Start Trial | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (La Jolla, CA) | Start Trial |
| Galeterone | Start Trial | C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity | University of Maryland (Baltimore, MD) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Galeterone
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Galeterone | World Intellectual Property Organization (WIPO) | WO2012142208 | 2031-04-13 | Start Trial |
| Galeterone | Austria | AT482969 | 2025-03-02 | Start Trial |
| Galeterone | Australia | AU2006218711 | 2025-03-02 | Start Trial |
| Galeterone | Brazil | BRPI0607523 | 2025-03-02 | Start Trial |
| Galeterone | Canada | CA2599953 | 2025-03-02 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
